Literature DB >> 12661847

A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.

S Singh1, B Mohan.   

Abstract

A pilot stability study was carried out on four fixed-dose combination anti-tuberculosis products at 40 degrees C and 75% RH. The strip-packed products were stable, while the blister-packed products showed both physical and chemical changes. The products in unpacked conditions showed severe (approximately 60%) decomposition of rifampicin and extensive physical changes. The main decomposition product in the solid state was isonicotinyl hydrazone of 3-formylrifamycin and isoniazid. It is suggested that attention should be paid to the detection and quantitation of this product in the marketed formulations. The packing material used in the manufacture of FDC products should also be of the highest quality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661847

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

1.  Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Authors:  Helen McIlleron; Peter Wash; André Burger; Jennifer Norman; Peter I Folb; Pete Smith
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  Bisoprolol and bisoprolol-valsartan compatibility studied by differential scanning calorimetry, nuclear magnetic resonance and X-ray powder diffractometry.

Authors:  Marcin Skotnicki; Juan A Aguilar; Marek Pyda; Paul Hodgkinson
Journal:  Pharm Res       Date:  2014-08-13       Impact factor: 4.200

3.  Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications.

Authors:  R Court; M T Chirehwa; L Wiesner; B Wright; W Smythe; N Kramer; H McIlleron
Journal:  Int J Tuberc Lung Dis       Date:  2018-05-01       Impact factor: 2.373

Review 4.  Substandard drugs: a potential crisis for public health.

Authors:  Atholl Johnston; David W Holt
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 5.  Current research toward optimizing dosing of first-line antituberculosis treatment.

Authors:  Helen McIlleron; Maxwell T Chirehwa
Journal:  Expert Rev Anti Infect Ther       Date:  2018-12-12       Impact factor: 5.091

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.